Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus

Jiun Ling Wang; Hung Jen Tang; Pang Hsin Hsieh; Fang Yao Chiu; Yen Hsu Chen; Ming Chau Chang; Ching Tai Huang; Chang Pan Liu; Yeu Jun Lau; Kao Pin Hwang; Wen Chien Ko; Chen Ti Wang; Cheng Yi Liu; Chien Lin Liu; Po Ren Hsueh

doi:10.1016/j.ijantimicag.2012.03.010

Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus

Jiun Ling Wang, Hung Jen Tang, Pang Hsin Hsieh, Fang Yao Chiu, Yen Hsu Chen, Ming Chau Chang, Ching Tai Huang, Chang Pan Liu, Yeu Jun Lau, Kao Pin Hwang, Wen Chien Ko, Chen Ti Wang, Cheng Yi Liu, Chien Lin Liu, Po Ren Hsueh

Research output: Contribution to journal › Short survey › peer-review

31 Citations (Scopus)

Abstract

There is a lack of surveillance data on resistance to fusidic acid (FA) in Asia, and no reviews of FA usage for the treatment of orthopaedic infections have been conducted since the year 2000. In this study, we present a systemic literature review of FA resistance in Asia and the clinical use of FA for the treatment of bone and joint infections (BJIs). The in vitro activity of FA against meticillin-resistant Staphylococcus aureus (MRSA) isolates remains good, with low (<10%) resistance rates in most Asian countries. FA in Asia appears to be a better oral anti-MRSA agent than trimethoprim/sulfamethoxazole and clindamycin. More than 80 cases of FA use for BJI have been reported since 2000 and the recurrence or failure rate is <10%. There is much evidence supporting the use of FA in combination with other antibiotics (e.g. rifampicin) as an oral treatment following intravenous glycopeptide treatment for BJIs.

Original language	English
Pages (from-to)	103-107
Number of pages	5
Journal	International journal of antimicrobial agents
Volume	40
Issue number	2
DOIs	https://doi.org/10.1016/j.ijantimicag.2012.03.010
Publication status	Published - 2012 Aug

All Science Journal Classification (ASJC) codes

Microbiology (medical)
Infectious Diseases
Pharmacology (medical)

Access to Document

10.1016/j.ijantimicag.2012.03.010

Cite this

Wang, J. L., Tang, H. J., Hsieh, P. H., Chiu, F. Y., Chen, Y. H., Chang, M. C., Huang, C. T., Liu, C. P., Lau, Y. J., Hwang, K. P., Ko, W. C., Wang, C. T., Liu, C. Y., Liu, C. L., & Hsueh, P. R. (2012). Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus. International journal of antimicrobial agents, 40(2), 103-107. https://doi.org/10.1016/j.ijantimicag.2012.03.010

@article{613f1829eab940a78d8c239632e5d60c,

title = "Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus",

abstract = "There is a lack of surveillance data on resistance to fusidic acid (FA) in Asia, and no reviews of FA usage for the treatment of orthopaedic infections have been conducted since the year 2000. In this study, we present a systemic literature review of FA resistance in Asia and the clinical use of FA for the treatment of bone and joint infections (BJIs). The in vitro activity of FA against meticillin-resistant Staphylococcus aureus (MRSA) isolates remains good, with low (<10%) resistance rates in most Asian countries. FA in Asia appears to be a better oral anti-MRSA agent than trimethoprim/sulfamethoxazole and clindamycin. More than 80 cases of FA use for BJI have been reported since 2000 and the recurrence or failure rate is <10%. There is much evidence supporting the use of FA in combination with other antibiotics (e.g. rifampicin) as an oral treatment following intravenous glycopeptide treatment for BJIs.",

author = "Wang, {Jiun Ling} and Tang, {Hung Jen} and Hsieh, {Pang Hsin} and Chiu, {Fang Yao} and Chen, {Yen Hsu} and Chang, {Ming Chau} and Huang, {Ching Tai} and Liu, {Chang Pan} and Lau, {Yeu Jun} and Hwang, {Kao Pin} and Ko, {Wen Chien} and Wang, {Chen Ti} and Liu, {Cheng Yi} and Liu, {Chien Lin} and Hsueh, {Po Ren}",

year = "2012",

month = aug,

doi = "10.1016/j.ijantimicag.2012.03.010",

language = "English",

volume = "40",

pages = "103--107",

journal = "International journal of antimicrobial agents",

issn = "0924-8579",

publisher = "Elsevier",

number = "2",

}

Wang, JL, Tang, HJ, Hsieh, PH, Chiu, FY, Chen, YH, Chang, MC, Huang, CT, Liu, CP, Lau, YJ, Hwang, KP, Ko, WC, Wang, CT, Liu, CY, Liu, CL & Hsueh, PR 2012, 'Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus', International journal of antimicrobial agents, vol. 40, no. 2, pp. 103-107. https://doi.org/10.1016/j.ijantimicag.2012.03.010

TY - JOUR

T1 - Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus

AU - Wang, Jiun Ling

AU - Tang, Hung Jen

AU - Hsieh, Pang Hsin

AU - Chiu, Fang Yao

AU - Chen, Yen Hsu

AU - Chang, Ming Chau

AU - Huang, Ching Tai

AU - Liu, Chang Pan

AU - Lau, Yeu Jun

AU - Hwang, Kao Pin

AU - Ko, Wen Chien

AU - Wang, Chen Ti

AU - Liu, Cheng Yi

AU - Liu, Chien Lin

AU - Hsueh, Po Ren

PY - 2012/8

Y1 - 2012/8

N2 - There is a lack of surveillance data on resistance to fusidic acid (FA) in Asia, and no reviews of FA usage for the treatment of orthopaedic infections have been conducted since the year 2000. In this study, we present a systemic literature review of FA resistance in Asia and the clinical use of FA for the treatment of bone and joint infections (BJIs). The in vitro activity of FA against meticillin-resistant Staphylococcus aureus (MRSA) isolates remains good, with low (<10%) resistance rates in most Asian countries. FA in Asia appears to be a better oral anti-MRSA agent than trimethoprim/sulfamethoxazole and clindamycin. More than 80 cases of FA use for BJI have been reported since 2000 and the recurrence or failure rate is <10%. There is much evidence supporting the use of FA in combination with other antibiotics (e.g. rifampicin) as an oral treatment following intravenous glycopeptide treatment for BJIs.

AB - There is a lack of surveillance data on resistance to fusidic acid (FA) in Asia, and no reviews of FA usage for the treatment of orthopaedic infections have been conducted since the year 2000. In this study, we present a systemic literature review of FA resistance in Asia and the clinical use of FA for the treatment of bone and joint infections (BJIs). The in vitro activity of FA against meticillin-resistant Staphylococcus aureus (MRSA) isolates remains good, with low (<10%) resistance rates in most Asian countries. FA in Asia appears to be a better oral anti-MRSA agent than trimethoprim/sulfamethoxazole and clindamycin. More than 80 cases of FA use for BJI have been reported since 2000 and the recurrence or failure rate is <10%. There is much evidence supporting the use of FA in combination with other antibiotics (e.g. rifampicin) as an oral treatment following intravenous glycopeptide treatment for BJIs.

UR - http://www.scopus.com/inward/record.url?scp=84864286748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864286748&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2012.03.010

DO - 10.1016/j.ijantimicag.2012.03.010

M3 - Short survey

C2 - 22612900

AN - SCOPUS:84864286748

SN - 0924-8579

VL - 40

SP - 103

EP - 107

JO - International journal of antimicrobial agents

JF - International journal of antimicrobial agents

IS - 2

ER -

Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this